Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: Inhibition by resveratrol

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Rajapakse, Angana G ^a   Yepuri, Gautham ^a   Carvas, João M ^a   Stein, Sokrates ^b   Matter, Christian M ^b   Scerri, Isabelle ^a   Ruffieux, Jean ^a   Montani, Jean Pierre ^a   Ming, Xiu Fen ^a   Yang, Zhihong ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MAMMALIAN TARGET OF RAPAMYCIN; MUTANT PROTEIN; NITRIC OXIDE; PROTEIN S6K1; RAPAMYCIN; RESVERATROL; SUPEROXIDE; UNCLASSIFIED DRUG; PROTEIN KINASE B; S6 KINASE; S6K1 PROTEIN, RAT; SMALL INTERFERING RNA; STILBENE DERIVATIVE;

AGE DISTRIBUTION; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RAT; SENESCENCE; SIGNAL TRANSDUCTION; ADENOVIRUS; ANIMAL; DRUG EFFECT; GENETICS; IMMUNOBLOTTING; IN VITRO STUDY; METABOLISM; WISTAR KYOTO RAT;

ANIMALIA; MAMMALIA; RATTUS;

ADENOVIRIDAE; AGING; ANIMALS; AORTA; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; IMMUNOBLOTTING; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED WKY; RIBOSOMAL PROTEIN S6 KINASES; RNA, SMALL INTERFERING; STILBENES; SUPEROXIDES;

EID: 79955526629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019237     Document Type: Article

References (52)

1. Najjar SS, Scuteri A, Lakatta EG, (2005) Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 46: 454-462.
2. Brandes RP, Fleming I, Busse R, (2005) Endothelial aging. Cardiovasc Res 66: 286-294.
3. van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, et al. (2000) Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 192: 1731-1744.
4. Tschudi MR, Barton M, Bersinger NA, Moreau P, Cosentino F, et al. (1996) Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest 98: 899-905.
5. Blagosklonny MV, (2008) Aging: ROS or TOR. Cell Cycle 7: 3344-3354.
6. Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK, (2009) The TOR pathway comes of age. Biochim Biophys Acta 1790: 1067-1074.
7. Jia K, Chen D, Riddle DL, (2004) The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 131: 3897-3906.
8. Kaeberlein M, Powers RW III, Steffen KK, Westman EA, Hu D, et al. (2005) Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 310: 1193-1196.
9. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, et al. (2004) Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 14: 885-890.
10. Powers RW III, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S, (2006) Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 20: 174-184.
11. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, et al. (2003) Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426: 620.
12. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, et al. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392-395.
13. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, et al. (2009) Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326: 140-144.
14. Chen C, Liu Y, Liu Y, Zheng P, (2009) mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2: ra75.
15. Polak P, Hall MN, (2009) mTOR and the control of whole body metabolism. Curr Opin Cell Biol 21: 209-218.
16. Bhaskar PT, Hay N, (2007) The two TORCs and Akt. Dev Cell 12: 487-502.
17. Ming XF, Rajapakse AG, Carvas JM, Ruffieux J, Yang Z, (2009) Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline. BMC Cardiovasc Disord 9: 12.
18. Linford NJ, Beyer RP, Gollahon K, Krajcik RA, Malloy VL, et al. (2007) Transcriptional response to aging and caloric restriction in heart and adipose tissue. Aging Cell 6: 673-688.
19. Rice KM, Kinnard RS, Wright GL, Blough ER, (2005) Aging alters vascular mechanotransduction: pressure-induced regulation of p70S6k in the rat aorta. Mech Ageing Dev 126: 1213-1222.
20. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
21. Labinskyy N, Csiszar A, Veress G, Stef G, Pacher P, et al. (2006) Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem 13: 989-996.
22. Finkel T, Deng CX, Mostoslavsky R, (2009) Recent progress in the biology and physiology of sirtuins. Nature 460: 587-591.
23. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
24. Zhang J, (2006) Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J 397: 519-527.
25. Dasgupta B, Milbrandt J, (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 104: 7217-7222.
26. Liu M, Wilk SA, Wang A, Zhou L, Wang RH, et al. (2010) Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 285: 36387-36394.
27. Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, et al. (2009) Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 1: 515-528.
28. Dolinsky VW, Chan AY, Robillard F I, Light PE, Des RC, et al. (2009) Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119: 1643-1652.
29. Demidenko ZN, Blagosklonny MV, (2009) At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle 8: 1901-1904.
30. Lee JH, Budanov AV, Park EJ, Birse R, Kim TE, et al. (2010) Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327: 1223-1228.
31. Li JM, Shah AM, (2004) Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287: R1014-R1030.
32. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, et al. (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450: 736-740.
33. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, et al. (2008) TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 205: 2397-2408.
34. Zou MH, Shi C, Cohen RA, (2002) Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109: 817-826.
35. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, et al. (1997) Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 17: 2479-2488.
36. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, et al. (2004) Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110: 3708-3714.
37. Rossi ML, Marziliano N, Merlini PA, Bramucci E, Canosi U, et al. (2005) Phenotype commitment in vascular smooth muscle cells derived from coronary atherosclerotic plaques: differential gene expression of endothelial nitric oxide synthase. Eur J Histochem 49: 39-46.
38. Stockklauser-Farber K, Ballhausen T, Laufer A, Rosen P, (2000) Influence of diabetes on cardiac nitric oxide synthase expression and activity. Biochim Biophys Acta 1535: 10-20.
39. Kazuyama E, Saito M, Kinoshita Y, Satoh I, Dimitriadis F, et al. (2009) Endothelial dysfunction in the early- and late-stage type-2 diabetic Goto-Kakizaki rat aorta. Mol Cell Biochem 332: 95-102.
40. Desrois M, Clarke K, Lan C, Dalmasso C, Cole M, et al. (2010) Upregulation of eNOS and unchanged energy metabolism in increased susceptibility of the aging type 2 diabetic GK rat heart to ischemic injury. Am J Physiol Heart Circ Physiol 299: H1679-H1686.
41. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG, (2000) Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 86: 347-354.
42. Hink U, Li H, Mollnau H, Oelze M, Matheis E, et al. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14-E22.
43. Rajapakse AG, Ming XF, Carvas JM, Yang Z, (2009) The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am J Physiol Heart Circ Physiol 296: H815-H822.
44. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, et al. (2010) Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299: H18-H24.
45. Pierce GL, Larocca TJ, (2008) Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults? J Physiol 586: 2673-2674.
46. Ghosh HS, McBurney M, Robbins PD, (2010) SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 5: e9199.
47. Sexton E, Van TC, LeBlanc K, Parent S, Lemoine P, et al. (2006) Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer 5: 45.
48. Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, et al. (2009) Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 8: 25-33.
49. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, et al. (2004) Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J 23: 212-220.
50. Ming XF, Rajapakse AG, Carvas JM, Ruffieux J, Yang Z, (2010) Opposing and uncoupling effects of mTOR and S6K1 in the regulation of endothelial tissue factor expression. FEBS Lett 584: 135-140.
51. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, et al. (2002) Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22: 8467-8477.
52. Yang YM, Huang A, Kaley G, Sun D, (2009) eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol 297: H1829-H1836.